Jun 2026 (Q2 FY26) — Aug 5, 2026
PACB Q2 FY26 — Spark Next Rollout and CEO Transition Amidst Revised Outlook
Read the full callPacific Biosciences of California (PACB) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Pacific Biosciences of California earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 39.0 | −1.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -114.4 | −1.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -44.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.84 +6.36% · +$0.11
Performance +12.2% 1Y
1Y: $1.64 on 17 Oct 2025 → $1.84. High $2.87 (5 Oct 2026), low $1.11 (12 Aug 2026).
- Previous close
- $1.73
- 52-week range
- $1.11 – $2.87
- One year
- −7.07%
Overview
- Symbol
- PACB
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Pacific Biosciences of California earnings calls (PACB)
Financials
What the filings say
Net profit, year on year: −7% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 39 | 37 | 40 | 38 | 45 | 37 | 39 |
| Operating profit | -64 | -153 | -429 | -45 | -39 | -41 | -8 | -45 |
| Operating margin | −160.3% | −390.1% | −1154.5% | −112.8% | −101.1% | −92.3% | −22.5% | −114.4% |
| Interest | 4 | 3 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | -61 | 3 | -426 | -42 | -38 | -40 | -8 | -45 |
| Tax rate | 0.0% | 11.8% | 0.1% | −0.1% | −1.0% | −0.5% | −2.3% | −0.1% |
| Net profit | -61 | 2 | -426 | -42 | -38 | -40 | -8 | -45 |
| EPS ($ per share) | -0.22 | — | -1.44 | -0.14 | -0.13 | — | -0.03 | -0.14 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -982 | -1,066 | -1,037 | -1,218 | -1,532 | -1,839 | -2,149 | -2,695 |
| Total liabilities | 56 | 93 | 78 | 1,216 | 1,204 | 1,045 | 754 | 779 |
| Fixed assets | 34 | 30 | 25 | 33 | 42 | 36 | 31 | 24 |
| Investments | 84 | 19 | 237 | 584 | 447 | 452 | 335 | 216 |
| Total assets | 170 | 148 | 414 | 2,007 | 1,767 | 1,746 | 1,260 | 784 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -66 | -78 | 20 | -111 | -263 | -259 | -206 | -111 |
| Cash from investing | -38 | 62 | -219 | -679 | 116 | 5 | 124 | 115 |
| Cash from financing | 107 | 27 | 252 | 1,170 | 10 | 109 | -43 | 3 |
| Net cash flow | — | — | — | 380 | -138 | -146 | -125 | 8 |
| Capital expenditure | -2 | -3 | -1 | -6 | -17 | -9 | -6 | -3 |
| Free cash flow | -68 | -81 | 18 | -117 | -280 | -268 | -212 | -114 |
Insider filings
20 filings between Feb 17, 2026 and Oct 6, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$3.37M
12 sales by 4 insiders
8% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 7
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Gibson James R II | — | $2.18M | Oct 6, 2026 |
| HENRY CHRISTIAN O | — | $771.3K | Mar 3, 2026 |
| Van Oene Mark | — | $334.6K | Aug 17, 2026 |
| Farmer Michele | — | $84.4K | Mar 3, 2026 |
Latest filings (36)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 6, 2026 | Gibson James R II See Remarks | Option exercise 10b5-1 plan | 500,000 | $590.0K |
| Oct 6, 2026 | Gibson James R II See Remarks | Sale 10b5-1 plan | 661,815 | $2.06M |
| Aug 17, 2026 | Van Oene Mark See Remarks | Sale | 26,911 | $30.4K |
| Aug 10, 2026 | Van Oene Mark See Remarks | Award | 489,130 | $0 |
| Apr 8, 2026 | Gibson Christopher Director | Award | 57,473 | $0 |
| Apr 1, 2026 | Gibson James R II See Remarks | Sale | 88,185 | $120.8K |
| Mar 3, 2026 | Gibson Christopher Director | Award | 53,913 | $0 |
| Mar 3, 2026 | HENRY CHRISTIAN O See Remarks | Sale | 12,497 | $18.9K |
| Mar 3, 2026 | Van Oene Mark See Remarks | Sale | 6,504 | $9.8K |
| Mar 3, 2026 | Farmer Michele See Remarks | Sale | 2,979 | $4.5K |
| Feb 27, 2026 | Gibson James R II See Remarks | Award | 333,848 | $0 |
| Feb 27, 2026 | Farmer Michele See Remarks | Award | 89,835 | $0 |
| Feb 27, 2026 | HENRY CHRISTIAN O See Remarks | Award | 920,810 | $0 |
| Feb 27, 2026 | Van Oene Mark See Remarks | Award | 500,000 | $0 |
| Feb 18, 2026 | Van Oene Mark See Remarks | Sale | 55,107 | $89.8K |
| Feb 18, 2026 | Farmer Michele See Remarks | Sale | 14,952 | $24.4K |
| Feb 18, 2026 | HENRY CHRISTIAN O See Remarks | Sale | 140,874 | $229.5K |
| Feb 17, 2026 | HENRY CHRISTIAN O See Remarks | Sale | 331,793 | $522.9K |
| Feb 17, 2026 | Van Oene Mark See Remarks | Sale | 129,790 | $204.5K |
| Feb 17, 2026 | Farmer Michele See Remarks | Sale | 35,215 | $55.5K |
| Aug 18, 2025 | Van Oene Mark See Remarks | Sale | 26,836 | $35.2K |
| May 19, 2025 | Farmer Michele See Remarks | Sale | 5,195 | $5.2K |
| Mar 31, 2025 | Gibson James R II See Remarks | Award | 1,000,000 | $0 |
| Mar 19, 2025 | Farmer Michele See Remarks | Award | 89,835 | $0 |
| Mar 19, 2025 | Van Oene Mark See Remarks | Award | 449,176 | $0 |
| Mar 19, 2025 | HENRY CHRISTIAN O See Remarks | Award | 920,810 | $0 |
| Mar 3, 2025 | HENRY CHRISTIAN O See Remarks | Sale | 12,497 | $17.6K |
| Mar 3, 2025 | Farmer Michele See Remarks | Sale | 2,973 | $4.2K |
| Mar 3, 2025 | Van Oene Mark See Remarks | Sale | 6,486 | $9.1K |
| Feb 18, 2025 | HENRY CHRISTIAN O See Remarks | Sale | 259,909 | $488.1K |
| Feb 18, 2025 | Farmer Michele See Remarks | Sale | 24,349 | $45.7K |
| Feb 18, 2025 | Van Oene Mark See Remarks | Sale | 100,773 | $189.3K |
| Jan 30, 2025 | Smith Christopher M Director | Award | 54,099 | $0 |
| Jan 10, 2025 | Van Oene Mark See Remarks | Sale | 34,405 | $70.0K |
| Sep 30, 2024 | Kim Susan G. See Remarks | Sale | 19,782 | $34.1K |
| Sep 16, 2024 | HENRY CHRISTIAN O See Remarks | Sale | 98,907 | $172.7K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Free account. Everything above stays public.
Write why you follow PACIFIC BIOSCIENCES OF CALIFORNIA, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading